Table 3.
Observed numbers (N), standardized incidence ratios (SIR), and 95 percent confidence intervals (CI) of second primary cancers by treatment for uterine corpus cancer.
| Second cancer | Surgery only | Surgery and radiotherapy | ||||
|---|---|---|---|---|---|---|
| N | SIR | 95% CI | N | SIR | 95% CI | |
| All cancers* | 4136 | 0.89 | 0.86–0.91 | 3292 | 1.02 | 0.99–1.06 |
| Solid cancers† | 3667 | 0.90 | 0.87–0.93 | 2871 | 1.02 | 0.98–1.06 |
| Buccal cavity and pharynx | 65 | 0.70 | 0.55–0.89 | 41 | 0.63 | 0.46–0.85 |
| Digestive system | 1074 | 0.91 | 0.85–0.96 | 978 | 1.14 | 1.07–1.22 |
| Esophagus | 17 | 0.52 | 0.32–0.84 | 13 | 0.56 | 0.32–0.96 |
| Stomach | 55 | 0.66 | 0.51–0.86 | 66 | 1.07 | 0.84–1.37 |
| Small intestine | 24 | 1.30 | 0.87–1.94 | 18 | 1.44 | 0.91–2.29 |
| Colon | 562 | 0.95 | 0.87–1.03 | 540 | 1.25 | 1.15–1.36 |
| Rectum | 110 | 0.92 | 0.76–1.11 | 109 | 1.27 | 1.05–1.53 |
| Liver | 18 | 0.64 | 0.40–1.01 | 17 | 0.89 | 0.55–1.43 |
| Gallbladder | 17 | 0.67 | 0.42–1.08 | 20 | 1.07 | 0.69–1.66 |
| Pancreas | 144 | 0.90 | 0.77–1.06 | 114 | 0.99 | 0.83–1.20 |
| Respiratory system | 534 | 0.68 | 0.63–0.74 | 443 | 0.84 | 0.77–0.92 |
| Lung and bronchus | 516 | 0.68 | 0.63–0.75 | 430 | 0.85 | 0.77–0.93 |
| Larynx | 9 | 0.42 | 0.22–0.80 | 9 | 0.60 | 0.31–1.16 |
| Breast | 1542 | 1.02 | 0.97–1.07 | 964 | 0.95 | 0.89–1.02 |
| Urinary system | 228 | 0.86 | 0.75–0.98 | 266 | 1.44 | 1.28–1.63 |
| Urinary bladder and ureter | 139 | 0.86 | 0.73–1.02 | 203 | 1.78 | 1.55–2.04 |
| Kidney | 79 | 0.88 | 0.71–1.10 | 44 | 0.73 | 0.55–0.99 |
| Renal pelvis | 8 | 0.69 | 0.34–1.37 | 13 | 1.56 | 0.90–2.68 |
| Bone | 5 | 1.10 | 0.46–2.63 | 6 | 1.91 | 0.86–4.26 |
| Soft tissue | 19 | 0.86 | 0.54–1.37 | 25 | 1.76 | 1.19–2.61 |
| Melanoma | 107 | 0.96 | 0.80–1.16 | 75 | 1.06 | 0.84–1.33 |
| Thyroid | 25 | 0.54 | 0.37–0.80 | 26 | 0.94 | 0.64–1.38 |
| Lymphatic and hematopoietic | 335 | 0.82 | 0.74–0.92 | 303 | 1.07 | 0.95–1.19 |
| Hodgkin lymphoma | 7 | 0.63 | 0.30–1.33 | 9 | 1.18 | 0.61–2.26 |
| Non-Hodgkin lymphoma | 172 | 0.81 | 0.70–0.94 | 155 | 1.07 | 0.91–1.25 |
| Multiple Myeloma | 59 | 0.86 | 0.66–1.11 | 44 | 0.90 | 0.67–1.21 |
| Non-CLL leukemia‡ | 60 | 0.92 | 0.71–1.19 | 71 | 1.55 | 1.23–1.96 |
| ALL | 3 | 0.83 | 0.27–2.59 | 4 | 1.65 | 0.62–4.39 |
| ANLL | 46 | 1.03 | 0.77–1.38 | 51 | 1.63 | 1.24–2.15 |
| CML | 11 | 0.65 | 0.36–1.17 | 16 | 1.32 | 0.81–2.16 |
| CLL | 37 | 0.73 | 0.53–1.01 | 24 | 0.65 | 0.44–0.98 |
*
Include all second cancers (excluding female genital system and non-melanoma skin cancer).
†
Include all solid second cancers (excluding female genital system and non-melanoma skin cancer)
‡
Non-chronic lymphocytic leukemia (CLL) includes acute lymphocytic leukemia (ALL), acute non-lymphocytic leukemia (ANLL), and chronic myeloid Leukemia (CML). Four patients with non CLL-leukemia in the surgery only group and two patients in the surgery and radiotherapy group were initially treated with chemotherapy.
Note: P <0.05 are in bold.